TMCnet News
Progenitor Life Sciences to Unveil Proprietary Next Generation "Off-the-Shelf" CAR-T Cell Development Workflow at the Biotech Showcase™ Annual ConferenceProgenitor Life Sciences LLC today announced that it will present at Biotech Showcase™ 2018, January 8-10, during JPMorgan Healthcare Conference week. Gary R. Sams, CEO, will present Wednesday January 10 at 10:45 a.m. PST. Progenitor Life Sciences has developed a proprietary workflow to enable the Next Generation CAR-T development, including proprietary technologies for both autologous and "Off-the-Shelf" allogeneic approaches to therapy. The company's technologies were developed by Progenitor in collaboration with the University of Utah. The company also announced that it will open discussions for a Series A investment round to fund further development of its platform and prosecution of IP. Sams stated, "We are excited to present at Biotech Showcase™. This event will be an extraordinary opportunity for Progenitor to highlight our unique CAR-T engineering platform, including new gene-switch technologies that allow control over CAR- activity in vivo using medically safe small molecules, or by 'programming' cells in advance to respond automatically to specific environmental cues. The next generation of CAR-T cells will be safer and smarter, and Progenitor is leading the way with proprietary technologies that will be at the core of these new therapies. We look forward to engaging parties at Biotech Showcase™ and JPM who have interest in participating in our Series A round, as well as strategic collaborators who want to use our platform." Biotech Showcase™, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences, the J.P. Morgan Annual Healthcare Conference. About Progenitor Life Sciences Progenitor Life Sciences provides unique and proprietary technologies to the rapidly growing immune oncology CAR-T development marketplace. The company is addressing key needs using proprietary genetic design approaches to enable next generation "off-the-shelf" allogeneic approaches, as well as, improved autologous approaches, to immune oncology CAR-T cell therapy development. The company's products and technologies provide unique proprietary genetic design tools and cell constructs, which are used in the preclinical drug discovery and development process. View source version on businesswire.com: http://www.businesswire.com/news/home/20180103005169/en/ |
